|
|
|||
|
|
||
|
|||
|
Cisbio Certifies Beckman Coulter`s PARADIGM™ Detection Platform for HTRF* Assays Fullerton, California (January 29, 2008) – Beckman Coulter, Inc. announced today that Cisbio International has awarded its homogenous time-resolved fluorescence (HTRF*) certification to the PARADIGM™ Detection Platform. Cisbio's certification verifies that the detection platform meets or exceeds performance criteria for HTRF assays. A new HTRF detection cartridge is now available for the unique, modular PARADIGM platform, bringing the growing total selection to 10. These detection cartridges can be interchanged in less than five minutes to meet different assay needs. PARADIGM, introduced earlier this year, is the first user-upgradeable and -configurable multimode reader. It is ideal for labs with multiple users and applications. The high-throughput detector reads on the fly, in formats from 6 to 1,536 wells. Cisbio's patented HTRF technology is incorporated into a growing selection of assays and reagents for drug discovery and screening. These popular assays produce superior results and are easily miniaturized and automated. "Beckman Coulter's application-focused, multifunctional detectors are very highly regarded and we are delighted that they have added an HTRF detection cartridge," commented François Degorce, head of HTRF marketing and business development at Cisbio. "This partnership with Cisbio is a great example of the flexibility that makes PARADIGM unique and successful," explained Jim Barry, marketing manager for Beckman Coulter. "Detection modes are difficult and costly to add to other multimode detectors once the systems are installed. Our detection cartridge system maximizes the users' return on investment and our instruments and automation platforms are already well-established in drug discovery and screening labs, where the use of TR-FRET assays, specifically HTRF are growing." Cisbio is a global developer of products and technologies used in nuclear medicine, in vitro diagnostics and assay development for drug screening procedures. The company pioneered the field of homogenous fluorescence methodologies via its proprietary technology, HTRF, a highly sensitive, robust technology for the detection of molecular interactions and widely used by the pharmaceutical industry for the high-throughput screening stage of drug development. In addition, Cisbio produces a selection of biological reagents and methods used by pharmaceutical and biotechnology companies, as well as contract research organizations (CROs). Headquartered in Saclay, France, Cisbio is owned by the Belgium consortium RadioPharma Partners and has facilities in Bagnols-sur-Cèze, France, Bedford, MA, U.S.A., and sales offices in Japan and India. For more information about Cisbio and HTRF, log onto www.cisbio.com and www.htrf.com. Beckman Coulter, Inc., based in Fullerton, California, develops, manufactures and markets products that simplify, automate and innovate complex biomedical tests. More than 200,000 Beckman Coulter systems operate in laboratories around the world supplying critical information for improving patient health and reducing the cost of care. Recurring revenue, consisting of supplies, test kits, service and operating-type lease payments, represents more than 75 percent of the company's 2006 annual revenue of $2.53 billion. For more information, visit www.beckmancoulter.com.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Back to Press Releases 
